Ancora Heart has entered a strategic partnership with digital health corporationEgnite to boost the enrolment of patients for the former’s CORCINCH-HF pivotal clinical study of the AccuCinch system.
The trial has been designed to assess the safety and efficacy of the AccuCinchventricular restoration system, which is a transcatheter device intended to help restore the structure and function of the heart’s enlarged left ventricle.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The Christ Health Network, located in Cincinnati, Ohio, was selected as the first site to deploy Egnite’s Trial Accelerator artificial intelligence (AI) technology in the CORCINCH-HF trial for the identification of eligible patients.
The company also plans to deploy Egnite’s AI technology at other participating CORCINCH-HF sites to support patient identification and enrolment for the study.
Egnite president and CEO Joel Portice said: “We believe this collaboration is a significant step forward for patients and are excited to be at the forefront of cardiovascular care.”
The Trial Accelerator technology will use AI and big data processing to expedite the recruitment of patients in the clinical study.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataIt will automatically screen several thousands of patients against trial parameters to enable the identification of more trial candidates without the support of hospital staff.
Ancora Heart chief commercial officer Mark Miles said: “Our goal with the development of the AccuCinch System is to provide a minimally invasive treatment option to further improve the lives of heart failure patients whose symptoms progress despite guideline-directed medical therapy.
“This partnership with Egnite and the Christ Health Network will allow us to deploy AI tools such as Egnite’s Trial Accelerator and expedite the identification of eligible candidates for the CORCINCH-HF trial.”
